News

Svetla Slavova, Ph.D., associate professor of biostatistics in the UK College of Public Health's Kentucky Injury Prevention and Research Center, will lead work that includes collaboration with the Kentucky All Schedule Prescription Electronic Reporting (KASPER) system, the Kentucky Office of Vital Statistics and the Office of the Chief Medical Examiner.

A multidisciplinary team of UK physicians and researchers will collaborate with additional specialists to develop diagnosis-specific educational materials to address opioid pain management options post-discharge, pain management alternatives to opioids and information on safe opioid use, storage and disposal.

PATHways and Beyond Birth program participant Bethany shares her recovery story to help others and thank those who helped her.

On this episode of "Behind the Blue," Sharon Walsh, director of the University of Kentucky’s Center on Drug and Alcohol Research (CDAR) and a distinguished professor in the UK College of Medicine, discusses the challenge Kentucky faces in battling the opioid epidemic.

Researchers at the University of Kentucky College of Medicine have discovered that targeting a specific signaling pathway could potentially provide a new therapeutic avenue for treating Fetal Alcohol Syndrome, the most severe fetal alcohol spectrum disorder.

Experts from the University of Kentucky on Thursday provided education, insight and information about the opioid epidemic to the UK Board of Trustees, campus leaders and community members.

A research facility expressly devoted to addressing and eradicating the state’s most significant health disparities was opened September 21st by the University of Kentucky Board of Trustees, President Eli Capilouto and many of the Commonwealth’s leading policymakers.

The new Center for Health Equity Transformation aims to grow health equity research at the University of Kentucky by training and providing professional development guidance to those interested in studying and addressing health disparities.

Don Helme is partnering with the Kentucky Attorney General’s office to gauge public opinion on a new drug deactivation pouch, part of a larger effort to develop solutions to the state’s opioid epidemic.

In an article recently published in the Journal of the American Medical Association, Drs. Lofwall and Walsh studied the efficacy and safety of buprenorphine delivered as a weekly or monthly injection for moderate-to-severe opioid use disorder.